Xspray Pharma AB publishes its Annual Report for 2024

REG

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today publishes its Annual Report for the financial year 2024.

An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma:

“In 2024, we finalized the foundation for Xspray Pharma’s transformation from an innovative, research-driven company into a commercial drug company. We have addressed regulatory challenges, conducted market preparations and secured funding to launch our first product, Dasynoc®, in the US market in 2025.”

The annual report is attached, and can also be downloaded from the company's website, www.xspraypharma.com.

Datum 2025-03-27, kl 08:00
Källa MFN
Ungdomsdeal - 200 kr ! Just nu får alla nya kunder mellan 18 och 25 år 200 kr gratis när man skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra läge att testa Nordnet!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet